Following the re-examination of its previous negative opinion, the European Medicines Agency has granted fampridine a conditional marketing authorisation; i.e. it has been licensed in Europe to improve the walking of PwMS who have walking disability.
Click here to read the EMA’s press release
“Common sense rules the day!”
CoI: I have acted as a consultant for Biogen-Idec in relation to the EMA’s orginal negative opinion.